Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$6.87 USD
+0.31 (4.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.89 +0.02 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ATNM 6.87 +0.31(4.73%)
Will ATNM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATNM
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
Other News for ATNM
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals' Iomab-B improves survival in refractory AML
Actinium Pharmaceuticals: A Strong Buy on Regulatory Advances and Strategic Positioning
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline